Objective: To address the regulation of circulating microRNAs in patients with stable coronary artery disease. Methods and Results: To determine the regulation of microRNAs, we performed a microRNA profile using RNA isolated from n‫8؍‬ healthy volunteers and n‫8؍‬ patients with stable coronary artery disease that received state-of-the-art pharmacological treatment. Interestingly, most of the highly expressed microRNAs that were lower in the blood of patients with coronary artery disease are known to be expressed in endothelial cells (eg, miR-126 and members of the miR-17ϳ92 cluster). To prospectively confirm these data, we detected selected microRNAs in plasma of 36 patients with coronary artery disease and 17 healthy volunteers by quantitative PCR. Consistent with the data obtained by the profile, circulating levels of miR-126, miR-17, miR-92a, and the inflammation-associated miR-155 were significantly reduced in patients with coronary artery disease compared with healthy controls. Likewise, the smooth muscle-enriched miR-145 was significantly reduced. In contrast, cardiac muscle-enriched microRNAs (miR-133a, miR-208a) tend to be higher in patients with coronary artery disease. These results were validated in a second cohort of 31 patients with documented coronary artery disease and 14 controls. 
M icroRNAs (miRNAs) are small (Ϸ22-nucleotide) noncoding RNAs regulating gene expression on the posttranscriptional level by binding to the target mRNA, leading either to degradation or to translational repression. 1 MiRNAs control development and are critically involved in many biological processes in health and disease including cardiovascular diseases. 1, 2 The crucial role of miRNAs in the cardiovascular system is supported by the finding that depletion of the miRNA-processing enzyme Dicer leads to defects in angiogenesis, vessel formation, and cardiac development. 1 In endothelial cells, several specific miRNAs have been identified to stimulate (let-7f, miR-27b, miR-130a) or inhibit (miR-221 and miR-222) angiogenesis in vitro. 3, 4 In particular, miR-126 was shown to be highly enriched in endothelial cells, and the expression of miR-126 is essential for vascular development. 5, 6 Moreover, members of the miR-17ϳ92 cluster were shown to modulate angiogenesis. 7, 8 The microRNAs miR-143 and miR-145 are highly expressed in smooth muscle cells and alter smooth muscle cell maintenance. 9 -11 MiR-1 and miR-133 are enriched in cardiomyocytes and control myogenesis, cardiac development, and hypertrophy. 12, 13 Finally, miR-208a and miR-208b are cardiac-specific miRNAs that are expressed by introns of myosin heavy chains and are involved in stress-dependent cardiac growth and gene expression. 14 MiRNAs were considered to act as intracellular RNAs to control gene expression on a posttranscriptional level. However, recent studies demonstrated that miRNAs can be detected in circulating blood and may be useful as biomarkers for disease. 15, 16 Surprisingly, miRNAs are present in serum or plasma in a remarkably stable form that even withstands repetitive freezing/thawing cycles and are protected against RNases. 15, 17 When human tumors were implanted in mice, specific human tumor-derived miRNAs have been detected in plasma. 15 Recent studies additionally suggested that circulating myocardial-derived miRNAs might be useful as potential biomarkers for infarction. 18 -22 In experimental acute myocardial infarction models and in patients, Wang et al showed that the muscle enriched miR-1, miR-133a, and miR-499, as well as the cardiac-specific miR-208, are elevated in the plasma. 18 Likewise, miR-499, 19 miR-1, 20,21 miR-133a/b, and miR-208 21, 22 were shown to be increased in small cohorts of humans after acute myocardial infarction. In patients with heart failure, circulating miR-423 was recently identified as potentially promising prognostic marker. 23 In patients with coronary artery disease (CAD), several miRNAs were shown to be dysregulated in isolated peripheral blood mononuclear cells. 24 The mechanism of how circulating miRNAs are released into the circulation is unclear. However, increasing evidence suggests that miRNAs are actively secreted in microvesicles. 16, 25, 26 Although the stimuli that trigger miRNA secretion are unclear, a recent study demonstrated that serum deprivation leads to the release of microRNAs in cell culture studies, 27 and miRNAs were detected in endothelial cellderived apoptotic bodies. 26 RNA or miRNAs, which have been incorporated in microvesicles or apoptotic bodies, were shown to be delivered into recipient cells. 16, 26, 28 However, whether the endogenous levels of circulating miRNAs regulate systemic gene expression needs to be further elucidated.
CAD is still the leading cause of death in the Western world. Endothelial activation is considered a first step in the development of atherosclerotic lesion, followed by invasion of proinflammatory cells and proliferation and dedifferentiation of smooth muscle cells. 29, 30 Several risk factors, such as hypercholesterolemia, are known to promote atherosclerosis, and various biomarkers were shown to identify patients at risk for CAD. However, the influence of endothelial activation and atherosclerotic disease, as well as the influence of current vasculoprotective therapy, on levels of circulating miRNAs is unknown. Therefore, we determined the levels of circulating miRNAs in patients with CAD.
Methods

Study Population
Thirty-six patients with CAD were included in the initial study cohort (derivation cohort) after angiographic documentation of CAD. Patients with impaired ejection fraction, heart failure, unstable CAD, or acute myocardial injury were excluded. Seventeen healthy volunteers without any evidence of CAD or inflammatory disorders served as the control group. General exclusion criteria were a known history of leukopenia, thrombocytopenia, or severe hepatic or renal dysfunction, as well as evidence for inflammatory or malignant disease. The results obtained in the derivation cohort were then prospectively tested in a validation cohort of 14 controls with angiographic exclusion of CAD and 31 patients with angiographically documented stable CAD. The ethics review board of the Goethe University Frankfurt, Germany, and the Landesärzk Kammer Heasen approved the protocols, and the study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from each individual (German Clinical Trials Register No. DRKS00000207).
RNA Isolation
RNA was isolated by using a TRIzol-based miRNA isolation protocol (TRIzol BD from Sigma). Because of high phenol contam- Figure 1 . Profile of circulating miRNAs in patients with CAD vs healthy volunteers. RNA was isolated from EDTAplasma from healthy volunteers (nϭ8) or patients with CAD (nϭ8). A heat map diagram is shown clustering the differentially expressed miRNAs.
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coronary artery disease miR microRNA miRNA microRNA qPCR quantitative PCR ination in these samples, additional isopropanol or ammonium precipitation steps were included. In addition, we used an miRNA kit provided by Qiagen (miRNeasy), which combines phenol/guanidinebased lysis of samples and silica membrane-based purification of total RNA (Ͼ18 nucleotides) in combination with the blood derivate-specific TRIzol BD from Sigma. These methods were tested in serum and plasma samples from healthy controls. The optimized protocol using the Qiagen miRNA kit was then used for all subsequent studies with 250 L of EDTA-plasma or serum. To date, no housekeeping miRNA has been established and validated to normalize for the miRNA content. Therefore, we supplemented the samples (after addition of TRIzol) with 5 nmol/L Caenorhabditis elegans miR-39 (cel-miR-39) as described previously. 15 We demonstrate that the cel-miR-39 can be used for normalization of the RNA preparation (Online Figure I , available at http://circres.ahajournals.org).
miRNA Profile
MiRNA profiles were obtained by hybridizing RNA from healthy volunteers and patients to a Geniom Biochip MPEA homo sapiens by Febit biomed GmbH (Heidelberg, Germany). The RNA concentration (optical density, 260/280) was similar between the patients and healthy volunteers. Data were corrected for background and were normalized by the mean intensity.
Detection and Quantification of miRNAs by Quantitative PCR
RNA was obtained as outlined above and diluted 1:10 (for all miRNAs except miR-208, which was added without dilution). Diluted RNA (5 L) was reverse transcribed using the TaqMan microRNA Reverse Transcription kit (ABI) according to the instructions of the manufacturer. Subsequently, 3 L of the product was used for detecting miRNA expression by quantitative (q)PCR using TaqMan microRNA Assay kits (ABI) for the corresponding microRNA. For the derivation cohort, values were normalized to cel-miR-39 and are expressed as 2
. For the validation cohort, we additionally used recombinant miRNAs to allow quantification of the circulating miRNAs (Online Figure II) . Values are given in picomolar concentrations of the miRNA and were normalized to cel-miR-39.
Statistics
All results for continuous variables are expressed as meansϮSEM, if not stated otherwise. For group-wise comparisons, Mann-Whitney test (2 groups), ANOVA, Kruskal-Wallis test (n groups), or Student's t test (2 groups) were used as appropriate. For categorical variables, Fischer's exact test or the 2 test were used. Spearman rank correlation or Pearson correlation were used to compare levels of microRNAs with classic clinical risk factors. All tests were performed 2-sided and a significance level of PϽ0.05 was considered to indicate statistical significance.
For all statistical analyses, the statistical software SPSS 15.0 (Statistical Package for the Social Sciences, Chicago, Ill) for Windows was used.
Results
Detection of Circulating miRNAs
To measure circulating miRNAs, we tested several miRNA isolation methods in serum and plasma samples from healthy controls. As shown in Online Figure III , the miRNA isolation kit (miRNeasy kit, Qiagen) revealed the best results to isolate miRNAs from EDTA-plasma or serum. These results were also confirmed for other miRNAs (miR-126) (data not shown). EDTA-plasma or serum also was superior to citrate plasma (data not shown). Although miRNAs were reliably Circulating miRNAs were detected by Geniom Biochips in RNA isolated from EDTA-plasma obtained from healthy volunteers (nϭ8) or patients with CAD (nϭ8).
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measurable, the absolute concentration of circulating miRNAs was Ͻ0.5% of the concentrations measured in heart tissue (Online Table I ).
Study Population of the Derivation Cohort
A total of 53 subjects were studied. Thirty-six patients had angiographically documented CAD. Seventeen individuals without evidence for CAD were selected as the control cohort. The clinical characteristics of the 2 study populations are summarized in Online Table II .
miRNA Profiles in Patients Versus Healthy Volunteers
To determine the influence of CAD on the levels of circulating miRNAs, we performed an miRNA profile using RNA isolated from nϭ8 patients with CAD and nϭ8 healthy controls. The clinical characteristics of the subgroups are shown in Online Table III . The levels of circulating miRNAs profoundly differed between patients and healthy controls, as illustrated in the heat map diagram shown in Figure 1 . Quantification revealed that multiple miRNAs were significantly downregulated in patients compared with healthy controls (Online Table IV ). Although the absolute number of significantly downregulated miRNAs prevailed, some circulating miRNAs were identified demonstrating increased levels in patients (Online Table V) . Interestingly, most if not all of the highly expressed and significantly downregulated miRNAs in patients with CAD are known to be expressed in the vascular wall, particularly in endothelial cells. These endothelial miRNAs include miR-126, members of the miR-17ϳ92 cluster (miR-17, miR-20a, miR-92a), miR-130a, miR-221, members of the let-7 family (let-7d), and miR-21 (Table) . In contrast to the high levels and profound regulation of endothelial and vascular miRNAs, cardiac miRNAs were detected at lower levels and were not downregulated. Interestingly, miR-208b was significantly upregulated in patients compared with healthy volunteers (Table) . The established smooth muscle-enriched miRNAs miR-143 and miR-145 did not differ between healthy controls and CAD patients in the profile (Table) .
To confirm the findings obtained by analyzing the miRNA profile, we measured the expression of selected miRNAs in the entire cohort of nϭ53 subjects by using TaqMan qPCR. As shown in Figure 2 , the predominantly endothelial expressed miRNAs miR-126, miR-17, and miR-92a, as well as the smooth muscle-enriched miR-145, were significantly reduced in patients with CAD, whereas cardiac muscleenriched miRNAs, such as miR-133 and miR-208a, were increased (Figure 2 ). In summary, these data demonstrate that CAD is associated with a significant decrease of circulating miRNAs that are preferentially expressed in endothelial cells or the vasculature, whereas prototypic muscle-enriched miRNAs were increased. In addition, we measured the expression of miR-155, which is processed from BIC, a noncoding transcript highly expressed in both activated B and T cells and in monocytes/macrophages but only weakly expressed in endothelial cells. 31 Circulating levels of miR-155 were significantly downregulated in patients with CAD, indicating that the downregulation of circulating miRNAs is not restricted to endothelial or vascular miRNAs.
Factors Influencing Circulating Levels of Endothelial miRNAs in Patients With CAD
To determine factors that influence the levels of circulating miRNAs, we analyzed the association with specific risk factors for CAD. Age was inversely correlated with the levels of circulating miR-155, and miR-155 was higher in females (Online Table VI ). None of the other circulating miRNAs was significantly associated with age or gender. MiR-155, miR-17, and miR-199 were significantly lower in diabetic patients (Online Table VI ). However, when only patients were included in the analysis, these miRNAs were not significantly different in patients with or without diabetes (data not shown). None of the miRNAs was associated with leukocyte counts. Interestingly, vascular and inflammation-linked miRNA (but not the cardiac-specific miR-208a) were highly influenced by vasculoprotective therapy with inhibitors of the renin-angiotensin system, aspirin and statins (Online Table  VI ). When the group of patients was selectively analyzed, statin therapy remained a significant factor (Online Table VII) , and a trend toward lower levels of miR-17, miR-92a, and miR-126 was detected in patients with statin therapy compared with patients without statin therapy (data not shown).
Validation Study
To verify the reduction of vascular and inflammation associated miRNAs in patients with CAD and to confirm the factors influencing the levels of circulating miRNAs, we prospectively measured circulating miRNAs in a validation cohort of control subjects without CAD (nϭ14) and patients with documented stable CAD (Nϭ31) (Online Table VIII ). As shown in Figure 3 , vascular and leukocyte-derived miRNA were significantly reduced in patients with CAD compared with controls, whereas cardiac miRNAs were slightly increased. Consistent with the influence of age and gender on miR-155 detected in the derivation cohort, females showed a significantly higher level of circulating miR-155 compared with males in the validation cohort ( Figure 4A ), and age was negatively associated with circulating miR-155 levels (PϽ0.001). Diabetes, again, was associated with significantly reduced levels of some vascular miRNAs in the entire validation cohort (miR-17 and miR-145: PϽ0.05). However, 
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when directly comparing the patients with or without diabetes, a trend can only be seen in miR-145 levels, which were further reduced in diabetic patients compared with patients with CAD but without diabetes ( Figure 4B ). Finally, confirming the results of our original cohort, statin treatment was associated with reduced levels of vascular miRNAs (miR-17: PϽ0.001; miR-145: PϽ0.05) and miR-155 (PϽ0.05). However, only miR-17 was significantly different, when exclusively CAD patients with statin therapy were compared with CAD patients without statin therapy (36Ϯ14% percent reduction; Pϭ0.024).
Discussion
The present study demonstrates that circulating vessel walland inflammatory cell-derived miRNAs can be detected in the blood and are regulated in patients with CAD. Interestingly, cardiac muscle-or skeletal muscle-derived miRNA were differentially regulated and tend to increase in stable patients with CAD. The data of the present study confirm previous reports showing that circulating miRNAs can be reliably isolated and measured in humans. 15, 20 The levels of miRNAs detected in plasma were slightly higher compared with serum, whereas others reported that similar concentrations of miRNAs can be isolated from plasma and serum. 15 However, the levels were correlating with each other and the dysregulation of miRNAs in CAD patients was detected when using both either plasma or serum to isolate miRNAs (see Figures 2 and 3 , respectively). Among the different plasma preparations studied, EDTA-plasma yielded the best results compared with citrateand heparin-plasma (data not shown). By supplementing the EDTA-plasma or serum samples with recombinant C elegans miRNAs, which can be specifically detected by TaqMan qPCR, differences in the efficiency of RNA isolation can be normalized. However, because of the profound regulation of multiple miRNAs and the unknown impact of factors that modulate circulating miRNA levels, we were unable to normalize the levels of circulating miRNAs by a "housekeeping" miRNA. Because "vascular" miRNAs were differentially regulated compared with cardiac miRNAs, unequal RNA concentration in the plasma appears unlikely to underlie the changes in expression levels detected between the groups in the present study.
Consistent with the exposure of the vasculature and inflammatory cells to the circulating blood, vascular wall-derived and leukocyte-derived miRNAs were detected in higher concentrations compared with skeletal or cardiac musclederived miRNAs in healthy volunteers, as well as in patients with CAD. Vascular miRNAs, including endothelial-enriched miRNAs (such as miR-126) or miRNAs that are highly expressed in endothelial cells (such as the miR-17ϳ92 cluster), were downregulated in patients with CAD, as shown in the miRNA profile, as well as in the derivation and validation study cohorts. Smooth muscle miRNAs were not significantly regulated in the profile, but we could detect a significant downregulation in the larger cohorts of patients. This discrepancy is likely attributable to the small sample size used to profile the miRNA levels. In contrast to the downregulation of most vascular-derived miRNAs in patients with CAD, circulating levels of skeletal muscle-or cardiacderived miRNAs showed a trend toward increased levels in patients with CAD. Although recent experimental studies showed that cardiac miRNAs are released after acute myocardial infarction, the increased levels are unlikely attributable to cardiac events, because the patients included in the present study had stable CAD and none of them showed Figure 4 . Effect of gender and diabetes on selected miRNAs. miRNAs were detected in the derivation and validation cohort by PCR and were normalized to cel-miR-39. A, miR-155 levels were detected in the derivation cohort (nϭ22 females, nϭ31 males) and the validation cohort (nϭ19 females, nϭ26 males). B, Influence of diabetes on circulating miRNA levels in the derivation cohort in healthy controls (HC) (Nϭ17), CAD (Nϭ27), and CAD with diabetes (Nϭ9) and in the validation cohort in healthy controls (Nϭ12), CAD (Nϭ23) and CAD patients with diabetes (Nϭ8). Note that the 2 individuals with diabetics but without CAD in the control group were excluded. Probability values are calculated by Mann-Whitney test in A and ANOVA in B.
elevated troponin T levels. However, we cannot exclude that the slight increase might be caused by a low grade of cardiac myocyte injury.
The reduced concentration of circulating vascular miRNAs detected in patients with CAD was surprising, because one would expect that endothelial activation, as it occurs in patients with CAD, induces the release of microparticles and remnants of apoptotic cells, thereby elevating the levels of miRNAs. However, recent experimental studies demonstrate that miRNA can be delivered by apoptotic bodies to atherosclerotic lesion. 26 Therefore, one may speculate that the reduction of circulating miRNAs detected in patients with CAD might be caused by an uptake of circulating miRNAs into atherosclerotic lesions.
One limitation of the present study is that we cannot provide molecular insights into the cause of the dysregulation. The levels of circulating miRNAs may be affected by multiple parameters such as the change in expression in the tissue, the release of the miRNAs by the cells into the circulation and the stability of miRNAs in the plasma. The simultaneous regulation of many vascular miRNAs may also reflect a modulation of miRNA processing, as it is known that cellular stressors can affect the expression of the enzyme Dicer that is essential for the biogenesis of mature miRNAs. 32 Further experimental studies are necessary to explore the mechanism(s), by which CAD and therapies affect tissue versus circulating miRNA levels.
In summary, the present study provides first insights into the levels of circulating miRNAs in patients with CAD. Besides confirming studies demonstrating the reliable measurement of circulating miRNAs, our study specifically addressed the levels and regulation of vascular and musclederived miRNAs and shows that, in particular, miRNAs that are highly expressed by endothelial cells can be detected in high concentrations in the circulation. Moreover, altered levels of miRNAs in CAD patients were detected in 2 patient cohorts. However, these data surely need to be confirmed in larger clinical populations, particularly because the analysis of single risk factors (such as diabetes) or therapeutic interventions is hampered by small numbers of patients available in these subcohorts. Furthermore, the mechanisms underlying the dysregulation, as well as the putative impact of the changes in circulating miRNAs levels in the physiology or pathophysiology, remains to be determined. Prospective large-scale studies are required to determine the potential use of circulating endothelial or vascular miRNAs as biomarkers for the development of CAD.
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